Logo

ACB

Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc. • NASDAQ
$4.60 ▲ 0.22% (+0.01)
Market Cap $260.25 M
52w High $6.91
52w Low $3.42
Dividend Yield 0%
P/E -6.39
Volume 277.91K
Outstanding Shares 56.58M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $88.198M $42.139M $31.669M 35.907% $-0.97 ▼ $39.441M
Q1-2026 $88.198M ▼ $42.139M ▼ $31.669M ▲ 35.907% ▲ $-0.36 ▲ $39.441M ▲
Q4-2025 $90.538M ▲ $52.294M ▲ $-24.557M ▼ -27.123% ▼ $-0.45 ▼ $-11.432M ▼
Q3-2025 $88.198M ▲ $42.139M ▼ $31.669M ▲ 35.907% ▲ $0.58 ▲ $39.441M ▲
Q2-2025 $81.122M $44.557M $-12.041M -14.843% $-0.22 $8.163M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $186.033M ▲ $837.839M ▼ $249.155M ▲ $551.92M ▼
Q4-2025 $138.475M ▲ $852.666M ▼ $244.075M ▼ $567.171M ▼
Q3-2025 $108.711M ▲ $866.521M ▲ $254.127M ▲ $572.919M ▲
Q2-2025 $84.921M ▼ $808.774M ▼ $225.801M ▼ $543.172M ▼
Q1-2025 $115.487M $838.689M $236.346M $561.618M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-14.725M ▲ $10.121M ▲ $-5.034M ▲ $-3.322M ▼ $705K ▼ $5.077M ▲
Q4-2025 $-21.984M ▼ $3.682M ▼ $-8.291M ▼ $8.701M ▲ $29.21M ▲ $-623K ▼
Q3-2025 $31.228M ▲ $28.839M ▲ $-3.212M ▲ $-5.575M ▼ $23.79M ▲ $23.981M ▲
Q2-2025 $1.675M ▼ $-24.891M ▼ $-3.638M ▼ $3.962M ▲ $-30.566M ▼ $-29.434M ▼
Q1-2025 $4.844M $8.375M $814K $-6.306M $2.048M $3.222M

Five-Year Company Overview

Income Statement

Income Statement Aurora’s income statement shows a company that has shrunk to a leaner size but has significantly improved its quality of earnings. Revenue has inched up recently after earlier declines, and gross profit has swung from losses to clearly positive territory, suggesting better pricing, mix, and cost control. Operating and net results, which used to be deeply negative, are now hovering around break-even, indicating that past restructuring and refocusing on medical markets are starting to show through. The key question going forward is whether this fragile return to profitability can be sustained and scaled, given the still-challenging industry backdrop.

Balance Sheet

Balance Sheet The balance sheet tells the story of a major cleanup and downsizing. Total assets and equity have fallen over several years, reflecting asset sales, write-downs, and the move away from an overbuilt footprint to a more focused core. Debt has been pared back to modest levels, which reduces financial risk, while cash has come down but not disappeared, suggesting a more disciplined use of resources. Overall, Aurora now looks smaller but financially sturdier than during its aggressive expansion phase, though the cushion is not especially thick.

Cash Flow

Cash Flow Cash flow has moved from consistently negative to roughly self-sustaining. Operating cash flow, which used to be a persistent drain, has recently tipped into positive territory, a notable turnaround for a cannabis producer. Capital spending is now very restrained, helping free cash flow move close to break-even, which fits with a strategy of sweating existing assets rather than chasing rapid expansion. The improvement is encouraging, but with only a modest buffer, any operational setbacks or regulatory shocks could quickly pressure liquidity again.

Competitive Edge

Competitive Edge Aurora’s competitive position rests less on sheer size and more on specialization and regulation-driven barriers. Its focus on the global medical cannabis market, backed by strict European quality certifications, gives it access to markets where not every producer can play and supports more stable, higher-margin demand than crowded recreational channels. Advanced, cost-efficient cultivation and a strong presence in key countries like Germany provide further differentiation, while the Bevo Farms stake adds a non-cannabis revenue base that can smooth volatility. The flip side is ongoing exposure to shifting medical regulations, tender processes, and intensifying competition from other global medical cannabis players chasing the same prize markets.

Innovation and R&D

Innovation and R&D Innovation and R&D are clear pillars of Aurora’s strategy rather than side projects. The company runs a sophisticated genetics and breeding program that targets higher yields, disease resistance, and specific aroma and potency profiles, which can boost margins and create distinct products. Recent work on auto-flowering traits, powdery mildew resistance, and aroma genetics, along with the Occo licensing platform, points toward a potential intellectual-property style moat that could generate higher-margin licensing revenue over time. The value of this innovation depends on successful commercialization at scale and on how quickly rivals catch up or regulatory frameworks evolve.

Summary

Aurora Cannabis today looks like a company that has taken painful medicine and is emerging smaller, more specialized, and more disciplined. Financially, it has moved from heavy losses and cash burn toward break-even profits and self-funded operations, with a cleaner balance sheet and less debt but also less room for error. Strategically, it has pivoted from chasing mass recreational volume in Canada to building a focused position in global medical cannabis, supported by strict quality certifications, genetics know-how, and diversified agriculture exposure via Bevo Farms. The main opportunities lie in expanding international medical sales and monetizing its genetics and R&D, while the main risks center on regulatory changes, competitive pressure in key medical markets, and the need to prove that recent financial improvements are durable rather than temporary.

NEWS

November 5, 2025 · 7:00 AM UTC

Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

Read more

October 22, 2025 · 5:15 PM UTC

Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call

Read more

September 18, 2025 · 7:00 AM UTC

Aurora Announces Investment into German Manufacturing Facility

Read more

September 9, 2025 · 7:00 AM UTC

Aurora and Copeia Launch English Version of Physician Experience Platform (PEP), Expanding Access to Peer-Reviewed Medical Cannabis Case Studies

Read more